Literature DB >> 35698638

Clinicopathologic profile of gastroenteropancreatic neuroendocrine neoplasms in a referral center of South India.

Temjen Sunup Jamir1, Bhawana Ashok Badhe2, Norton Stephen3, Bheemanathi Hanuman Srinivas4, Biju Pottakkat5.   

Abstract

BACKGROUND: The neuroendocrine system of the gastroenteropancreatic (GEP) region gives rise to unique, heterogeneous malignancies that need a high index of suspicion to make a diagnosis owing to their indolent course. AIMS: The present study aimed to find the incidence and the differences in the morphologic and immunohistochemical profile of gastroenteropancreatic neuroendocrine tumors (GEPNET) in a referral center of South India, JIPMER, Puducherry, India.
METHODS: There were 55 gastroenteropancreatic region neuroendocrine neoplasms (NEN) assessed for demographic, clinical and radiological features. Gross morphological features, histopathological features, mitotic index, Ki67 proliferation index, and immunohistochemical positivity for synaptophysin, chromogranin-A, CD-56, NSE (Neuron Specific Enolase) and pan-cytokeratin (Pan-CK) were also assessed.
RESULTS: The majority were nonfunctional tumors presenting with abdominal pain, gastrointestinal bleed, vomiting, jaundice, and loss of weight and appetite. The sites of involvement according to the order of frequency were duodenum, stomach, rectum, pancreas, ileum, appendix and jejunum. The endoscopic appearance of duodenal and jejunal tumors showed polypoidal, nodular and ulceroproliferative growth. These tumors were diagnosed by preoperative biopsy; 54% of them were grade-1 neuroendocrine tumors exhibiting nesting, trabecular, cord, and solid sheet patterns. All 55 cases were synaptophysin-positive with variable positivity for chromogranin, neuron-specific enolase, CD56, and Pan-CK. Mixed adenoneuroendocrine carcinomas (MANECs) involving the duodenum and stomach comprised 7.3% of all GEPNETs. Pancreatic neuroendocrine tumors constituted 9% of all tumors; one was multifocal. Lymph node metastasis was seen in 12/55 tumors; 6/12 showed liver metastasis also. All metastasizing tumors measured less than 4 cm in size. Statistical correlation of the tumor grade, mitotic count and Ki67 index as analysed by Spearman's correlation between the paired data denoted by rs in 55 tumors showed a strong correlation between mitotic count and Ki67 index; a moderate correlation was noted between the tumor grade and Ki67 index.
CONCLUSION: The clinicopathologic profile of 55 GEPNET revealed a majority to be sporadic Grade 1 tumor. Tumors that showed lymph node and liver metastasis were less than 4 cm in size. MANECs were found in the duodenum and stomach. IJCEP
Copyright © 2022.

Entities:  

Keywords:  Gastroenteropancreatic neuroendocrine tumors; immunohistochemistry; mixed neuroendocrine-non-neuroendocrine neoplasms

Year:  2022        PMID: 35698638      PMCID: PMC9187919     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  29 in total

1.  Prognosis of carcinoid heart disease: analysis of 200 cases over two decades.

Authors:  Jacob E Møller; Patricia A Pellikka; Alain M Bernheim; Hartzell V Schaff; Joseph Rubin; Heidi M Connolly
Journal:  Circulation       Date:  2005-11-14       Impact factor: 29.690

2.  Expression of intermediate filaments in neuroendocrine tumors.

Authors:  N Kimura; Y Nakazato; H Nagura; N Sasano
Journal:  Arch Pathol Lab Med       Date:  1990-05       Impact factor: 5.534

Review 3.  Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Authors:  R Garcia-Carbonero; J Capdevila; G Crespo-Herrero; J A Díaz-Pérez; M P Martínez Del Prado; V Alonso Orduña; I Sevilla-García; C Villabona-Artero; A Beguiristain-Gómez; M Llanos-Muñoz; M Marazuela; C Alvarez-Escola; D Castellano; E Vilar; P Jiménez-Fonseca; A Teulé; J Sastre-Valera; M Benavent-Viñuelas; A Monleon; R Salazar
Journal:  Ann Oncol       Date:  2010-02-05       Impact factor: 32.976

Review 4.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Jill M Weber; Max Feldman; Domenico Coppola; Kenneth Meredith; Larry K Kvols
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

6.  Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors.

Authors:  B Al-Khafaji; A E Noffsinger; M A Miller; G DeVoe; G N Stemmermann; C Fenoglio-Preiser
Journal:  Hum Pathol       Date:  1998-09       Impact factor: 3.466

7.  Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.

Authors:  C Lombard-Bohas; E Mitry; D O'Toole; C Louvet; D Pillon; G Cadiot; F Borson-Chazot; T Aparicio; M Ducreux; T Lecomte; P L Etienne; W Cacheux; J L Legoux; J F Seitz; P Ruszniewski; J A Chayvialle; P Rougier
Journal:  Neuroendocrinology       Date:  2008-08-22       Impact factor: 4.914

Review 8.  Gastroenteropancreatic neuroendocrine tumours.

Authors:  Irvin M Modlin; Kjell Oberg; Daniel C Chung; Robert T Jensen; Wouter W de Herder; Rajesh V Thakker; Martyn Caplin; Gianfranco Delle Fave; Greg A Kaltsas; Eric P Krenning; Steven F Moss; Ola Nilsson; Guido Rindi; Ramon Salazar; Philippe Ruszniewski; Anders Sundin
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

9.  Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.

Authors:  Yu-Hong Wang; Yuan Lin; Ling Xue; Jin-Hui Wang; Min-Hu Chen; Jie Chen
Journal:  BMC Endocr Disord       Date:  2012-11-29       Impact factor: 2.763

10.  Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.

Authors:  Patricia Mjønes; Liv Sagatun; Ivar S Nordrum; Helge L Waldum
Journal:  J Histochem Cytochem       Date:  2017-10-03       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.